BACKGROUND
ORCHARD (NCT03944772) was a biomarker-directed, phase II, platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) following progression on first-line osimertini...
J. Goldman, J. W. Riess, Byoung Chul Cho et al.· Clinical Lung Cancer· 0 citations
CEACAM1 homodimerization mediates tumor immune evasion, presenting a compelling target to overcome resistance to PD-1 blockade. However, defining a precise structural and pharmacological blueprint for CEACAM1 targeting has remained challenging. Here, we report the discovery and comprehensive preclinical characterizatio...
Jae-Chul Lee, Miyoung Oh, H. Nam et al.· Molecular Cancer Therapeutic...· 0 citations
The evidence of clinical efficacy in a pretreated population, favorable tolerability and low rate of treatment discontinuation observed in Parts A and B support further evaluation of rilvegostomig in Parts C-E of the study, which assess safety and efficacy in CPI-naïve patients with nonsquamous and/or squamous NSCLC.
K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al.· Clinical Cancer Research· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.